19:54 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Esperion hypercholesterolemia candidate meets in fifth and final Phase III

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) as monotherapy met the primary endpoint of reducing LDL-C in the Phase III CLEAR Wisdom (1002-047) trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
18:51 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Esperion combo lowers LDL-C in Phase III for high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
19:45 , Aug 27, 2018 |  BC Extra  |  Clinical News

Esperion combo lowers LDL-C in high-risk ASCVD

Esperion Therapeutics Inc. (NASDAQ:ESPR) said its bempedoic acid/ezetimibe combination pill met the primary endpoint of reducing LDL-C in the Phase III 1002-053 trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients on maximally...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
15:29 , May 25, 2018 |  BC Week In Review  |  Clinical News

Esperion's hypercholesterolemia candidate meets in Phase III

Esperion Therapeutics Inc. (NASDAQ:ESPR) said once-daily 180 mg oral bempedoic acid (ETC-1002) met the primary endpoint of reducing LDL-C from baseline to week 12 vs. placebo (23% vs. 1%, p<0.001) in the Phase III CLEAR...
16:09 , May 4, 2018 |  BC Week In Review  |  Clinical News

Esperion reports Phase III data for hypercholesterolemia candidate

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) met the primary safety endpoint and key secondary efficacy endpoint in the Phase III CLEAR Harmony (1002-040) trial to treat high-risk atherosclerotic cardiovascular disease (ASCVD) patients with...
16:51 , May 2, 2018 |  BC Extra  |  Clinical News

Esperion falls on Phase III data for hypercholesterolemia candidate

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) met the primary safety endpoint and key secondary efficacy endpoint in the Phase III CLEAR Harmony (1002-040) trial to treat high-risk atherosclerotic cardiovascular disease (ASCVD) patients with...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
18:58 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Esperion reports first Phase III hypercholesterolemia data

Esperion Therapeutics Inc. (NASDAQ:ESPR) said once-daily oral bempedoic acid (ETC-1002) met the primary endpoint in the Phase III CLEAR Tranquility (1002-048) trial to treat hypercholesterolemia in patients with atherosclerotic cardiovascular disease (ASCVD). The company also...